2010
DOI: 10.1007/s00103-010-1178-9
|View full text |Cite
|
Sign up to set email alerts
|

Möglichkeiten und Limitationen psychopharmakologischer Interventionen bei psychischer Komorbidität

Abstract: Comorbid depressive and anxiety disorders are associated with chronic physical illnesses. Treatment with antidepressants and mood stabilizers require knowledge about toxicity, potential side effects, and drug interactions. According to controlled studies in comorbid cardiovascular diseases, diabetes mellitus, and cerebrovascular disorders (post-stroke depression), serotonin-selective reuptake inhibitors (SSRIs), e.g., sertraline and citalopram, are preferred. Pramipexole, reboxetine, mirtazapine, or nortriptyl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2011
2011
2013
2013

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 24 publications
0
1
0
1
Order By: Relevance
“…Most publications report on pramipexole. Also reboxetine, mirtazapine, and nortriptyline are effective in treatment of depression in Parkinson patients [11]. But in order to diminish the amount of medication and to avoid possible side effects of additional antidepressants—because it acts both on Parkinson symptoms and depression—pramipexole is seen as an alternative to antidepressant drugs in depressed Parkinson patients [12].…”
Section: Treatment Options For Comorbid Parkinson's and Bipolar Pamentioning
confidence: 99%
“…Most publications report on pramipexole. Also reboxetine, mirtazapine, and nortriptyline are effective in treatment of depression in Parkinson patients [11]. But in order to diminish the amount of medication and to avoid possible side effects of additional antidepressants—because it acts both on Parkinson symptoms and depression—pramipexole is seen as an alternative to antidepressant drugs in depressed Parkinson patients [12].…”
Section: Treatment Options For Comorbid Parkinson's and Bipolar Pamentioning
confidence: 99%
“…Patienten im psychiatrischen Konsildienst sind signifikant älter als Patienten in einer stationär-psychiatrischen Behandlung. Aufgrund dessen müssen im psychiatrischen Konsildienst therapeutische Empfehlungen hinsichtlich Wahl des Psychopharmakons, Eindosierungszeit und Zieldosis entsprechend angepasst werden [13]. Die Gruppe älterer männlicher Patienten unterscheidet sich wohl am meisten von den stationär-psychiatrischen Patienten und stellt im psychiatrischen Konsildienst wahrscheinlich die größte Herausforderung dar, da diese im Allgemeinen eine eher ablehnende Haltung gegenüber psychischen Erkrankungen einnimmt [14] und von sich aus wohl keinen Kontakt zu einer psychiatrischen oder psychotherapeutischen Behandlung herstellen würde.…”
unclassified